Quest Laboratories Ltd Hits Lower Circuit Amid Heavy Selling Pressure

Market Performance and Price Action

On 4 Mar 2026, Quest Laboratories Ltd (Stock ID: 10039259) recorded a significant downturn, underperforming both its sector and the broader market indices. The stock’s 1-day return stood at -4.97%, compared to the Pharmaceuticals & Biotechnology sector’s decline of -1.56% and the Sensex’s fall of -2.03%. This marked underperformance highlights the stock’s vulnerability amid current market conditions.

The stock’s price band was set at 5%, and it reached the lower circuit at ₹109.05, with an intraday low of ₹109.05 and a high of ₹110.00. The total traded volume was 0.264 lakh shares, generating a turnover of ₹0.29 crore. Despite the relatively modest turnover, the stock’s liquidity remains adequate for small trade sizes, with a 2% threshold of the 5-day average traded value supporting trades up to ₹0.01 crore.

Technical Indicators and Investor Behaviour

From a technical standpoint, Quest Laboratories Ltd’s price remains above its 50-day, 100-day, and 200-day moving averages, signalling a longer-term support base. However, it is trading below its 5-day and 20-day moving averages, indicating short-term weakness and a possible bearish momentum. This divergence suggests that while the stock has underlying strength, recent selling has eroded near-term confidence.

Investor participation has notably declined, with delivery volumes on 2 Mar 2026 falling by 32.62% to 22,800 shares compared to the 5-day average. This drop in delivery volume points to reduced conviction among buyers, further exacerbating the selling pressure. The combination of falling participation and circuit hitting price action often signals panic selling and unfilled supply in the market.

Fundamental Context and Market Capitalisation

Quest Laboratories Ltd operates within the Pharmaceuticals & Biotechnology industry, a sector that has seen mixed performance amid evolving regulatory and market dynamics. The company’s market capitalisation stands at ₹180 crore, categorising it as a micro-cap stock. This size often entails higher volatility and susceptibility to market sentiment swings, as evidenced by the recent price action.

Despite the recent setback, the company maintains a Mojo Score of 74.0, reflecting a favourable overall assessment. Its Mojo Grade was recently downgraded from Strong Buy to Buy on 2 Mar 2026, signalling a slight moderation in analyst enthusiasm but still indicating a positive outlook. The Market Cap Grade is 4, suggesting moderate market capitalisation quality relative to peers.

Implications of Lower Circuit Hit and Investor Sentiment

Hitting the lower circuit limit is a clear indication of intense selling pressure that overwhelmed buying interest during the trading session. Such a move often results from panic selling triggered by negative news, earnings concerns, or broader market weakness. In Quest Laboratories Ltd’s case, the unfilled supply at the lower price level suggests that sellers were eager to exit positions, but buyers were reluctant to step in, causing the stock to close at the maximum permissible loss for the day.

This scenario can lead to heightened volatility in subsequent sessions as investors reassess valuations and risk. For micro-cap stocks like Quest Laboratories Ltd, circuit hits can also attract speculative trading and increased attention from short-term traders, which may amplify price swings.

Outlook and Investor Considerations

Investors should approach Quest Laboratories Ltd with caution in the near term, given the recent volatility and circuit hit. While the stock’s longer-term moving averages suggest underlying support, the short-term technical weakness and falling delivery volumes indicate a cautious market stance. The downgrade from Strong Buy to Buy also reflects a tempered outlook from analysts, possibly due to sector headwinds or company-specific challenges.

For those considering entry, it is advisable to monitor trading volumes and price action closely in the coming sessions to gauge whether the selling pressure abates or intensifies. Additionally, keeping an eye on sector trends and broader market movements will be crucial, as Pharmaceuticals & Biotechnology stocks can be sensitive to regulatory developments and macroeconomic factors.

Given the micro-cap status of Quest Laboratories Ltd, liquidity constraints and price volatility remain key risks. Investors with a higher risk appetite may find opportunities in the stock’s current valuation, but should be prepared for potential sharp price fluctuations.

Summary

Quest Laboratories Ltd’s fall to the lower circuit on 4 Mar 2026 underscores the challenges faced by micro-cap stocks in volatile markets. The maximum daily loss of 4.97% amid heavy selling pressure and reduced investor participation highlights a period of uncertainty. While the company retains a positive Mojo Score and a Buy rating, the downgrade from Strong Buy and technical indicators suggest a cautious stance is warranted. Investors should weigh the risks of panic selling and unfilled supply against the stock’s fundamental prospects before making decisions.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today